دورية أكاديمية
أعرض في EDS

Involvement of the IL-6 Signaling Pathway in the Anti-Anhedonic Effect of the Antidepressant Agomelatine in the Chronic Mild Stress Model of Depression.

التفاصيل البيبلوغرافية
العنوان: Involvement of the IL-6 Signaling Pathway in the Anti-Anhedonic Effect of the Antidepressant Agomelatine in the Chronic Mild Stress Model of Depression.
المؤلفون: Rossetti AC; Department of Medical Biotechnology and Translational Medicine, University of Milan, 20129 Milan, Italy., Paladini MS; Department of Medical Biotechnology and Translational Medicine, University of Milan, 20129 Milan, Italy., Brüning CA; Center for Chemical, Pharmaceutical and Food Sciences (CCQFA), Federal University of Pelotas, Pelotas 96010-900, RS, Brazil., Spero V; Department of Medical Biotechnology and Translational Medicine, University of Milan, 20129 Milan, Italy., Cattaneo MG; Department of Medical Biotechnology and Translational Medicine, University of Milan, 20129 Milan, Italy., Racagni G; Department of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy., Papp M; Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Krakow, Poland., Riva MA; Department of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.; Biological Psychiatry Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy., Molteni R; Department of Medical Biotechnology and Translational Medicine, University of Milan, 20129 Milan, Italy.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2022 Oct 18; Vol. 23 (20). Date of Electronic Publication: 2022 Oct 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Interleukin-6*/genetics , Interleukin-6*/metabolism , Depressive Disorder, Major*/drug therapy, Animals ; Rats ; Male ; Depression/drug therapy ; Depression/etiology ; Depression/metabolism ; Rats, Wistar ; Antidepressive Agents/pharmacology ; Antidepressive Agents/therapeutic use ; Signal Transduction ; Inflammation Mediators/metabolism ; Suppressor of Cytokine Signaling Proteins/metabolism ; Sucrose
مستخلص: Neuroinflammation has emerged as an important factor in the molecular underpinnings of major depressive disorder (MDD) pathophysiology and in the mechanism of action of antidepressants. Among the inflammatory mediators dysregulated in depressed patients, interleukin (IL)-6 has recently been proposed to play a crucial role. IL-6 activates a signaling pathway comprising the JAK/STAT proteins and characterized by a specific negative feedback loop exerted by the cytoplasmic protein suppressor of cytokine signalling-3 (SOCS3). On these bases, here, we explored the potential involvement of IL-6 signaling in the ability of the antidepressant drug agomelatine to normalize the anhedonic-like phenotype induced in the rat by chronic stress exposure. To this aim, adult male Wistar rats were subjected to the chronic mild stress (CMS) paradigm and chronically treated with vehicle or agomelatine. The behavioral evaluation was assessed by the sucrose consumption test, whereas molecular analyses were performed in the prefrontal cortex. We found that CMS was able to stimulate IL-6 production and signaling, including SOCS3 gene and protein expression, but the SOCS3-mediated feedback-loop inhibition failed to suppress the IL-6 cascade in stressed animals. Conversely, agomelatine treatment normalized the stress-induced decrease in sucrose consumption and restored the negative modulation of the IL-6 signaling via SOCS3 expression and activity. Our results provide additional information about the pleiotropic mechanisms that contribute to agomelatine's therapeutic effects.
References: Biochem Biophys Res Commun. 2010 Apr 16;394(4):976-80. (PMID: 20307495)
World J Biol Psychiatry. 2018 Aug;19(5):390-401. (PMID: 28337940)
Chronic Stress (Thousand Oaks). 2021 Aug 29;5:24705470211029254. (PMID: 34485797)
Neuropsychopharmacol Rep. 2020 Jun;40(2):130-137. (PMID: 32162496)
Pharmacol Biochem Behav. 2016 Nov - Dec;150-151:138-146. (PMID: 27769904)
Neurochem Int. 2017 Jan;102:114-122. (PMID: 28012846)
Biol Psychiatry. 2010 Mar 1;67(5):446-57. (PMID: 20015486)
Psychoneuroendocrinology. 2013 Jan;38(1):122-34. (PMID: 22663897)
Eur J Neurosci. 2021 Jan;53(1):151-171. (PMID: 32150310)
Cell Mol Life Sci. 2016 Sep;73(17):3323-36. (PMID: 27137184)
Neurobiol Stress. 2016 Aug 24;6:78-93. (PMID: 28229111)
JAMA Psychiatry. 2014 Dec 1;71(12):1381-91. (PMID: 25322082)
Behav Brain Res. 2019 May 17;364:494-502. (PMID: 28572058)
Transl Psychiatry. 2019 Apr 3;9(1):127. (PMID: 30944309)
Nat Immunol. 2017 Oct 18;18(11):1271. (PMID: 29044237)
Physiol Behav. 2016 Jul 1;161:15-23. (PMID: 27063246)
Front Immunol. 2017 Feb 08;8:70. (PMID: 28228755)
Immunity. 2019 Apr 16;50(4):1007-1023. (PMID: 30995492)
J Immunol. 2007 Nov 1;179(9):5966-76. (PMID: 17947670)
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):744-59. (PMID: 20828592)
Biomed Res Int. 2021 Mar 17;2021:6664591. (PMID: 33791372)
Pharmacoeconomics. 2020 Jan;38(1):25-37. (PMID: 31646432)
Psychosom Med. 2009 Feb;71(2):171-86. (PMID: 19188531)
Expert Opin Ther Targets. 2014 May;18(5):495-512. (PMID: 24548241)
Neuron. 2013 Jul 10;79(1):16-29. (PMID: 23849196)
Curr Protoc Pharmacol. 2012 Jun;Chapter 5:Unit 5.9. (PMID: 22684722)
Mol Psychiatry. 2017 Oct;22(10):1448-1454. (PMID: 28138158)
Mol Psychiatry. 2016 Dec;21(12):1696-1709. (PMID: 26903267)
Mol Pharmacol. 2012 May;81(5):657-68. (PMID: 22311708)
J Affect Disord. 2012 Aug;139(3):230-9. (PMID: 21872339)
Brain Behav Immun. 2016 Oct;57:293-303. (PMID: 27223094)
Front Cell Neurosci. 2021 Jul 02;15:691067. (PMID: 34276311)
World J Biol Chem. 2014 May 26;5(2):231-9. (PMID: 24921012)
Brain Behav Immun. 2016 Nov;58:261-271. (PMID: 27474084)
Br J Pharmacol. 2018 Aug;175(16):3263-3280. (PMID: 28707298)
Pharmacol Res. 2016 Jan;103:1-12. (PMID: 26535964)
Cell Commun Signal. 2019 May 17;17(1):46. (PMID: 31101051)
Bone. 2014 Oct;67:166-74. (PMID: 25016096)
Neuropsychopharmacology. 2008 Jun;33(7):1545-58. (PMID: 17700647)
Eur Neuropsychopharmacol. 2013 Nov;23(11):1645-55. (PMID: 23622958)
Eur Cytokine Netw. 2013 Jun;24(2):97-103. (PMID: 23823083)
J Psychiatr Res. 2013 Jun;47(6):802-8. (PMID: 23522402)
Cell Signal. 2015 Mar;27(3):555-67. (PMID: 25562430)
Brain Behav Immun. 2020 Jul;87:901-909. (PMID: 32113908)
Semin Immunol. 2014 Feb;26(1):13-9. (PMID: 24418198)
Front Physiol. 2014 Sep 17;5:355. (PMID: 25278904)
J Neurol Neurosurg Psychiatry. 2020 Jan;91(1):21-32. (PMID: 31658959)
Br J Pharmacol. 2014 Aug;171(15):3604-19. (PMID: 24724693)
Exp Biol Med (Maywood). 2016 Mar;241(5):509-18. (PMID: 26643864)
Cell. 2020 Jul 23;182(2):372-387.e14. (PMID: 32610084)
Int J Neuropsychopharmacol. 2016 Sep 21;19(9):. (PMID: 27207922)
Neurobiol Dis. 2006 Sep;23(3):587-94. (PMID: 16843000)
Neurobiol Dis. 2016 May;89:46-54. (PMID: 26804030)
فهرسة مساهمة: Keywords: SOCS3; major depressive disorder; neuroinflammation; prefrontal cortex; stress
المشرفين على المادة: 0 (Interleukin-6)
0 (Antidepressive Agents)
0 (Inflammation Mediators)
0 (Suppressor of Cytokine Signaling Proteins)
57-50-1 (Sucrose)
تواريخ الأحداث: Date Created: 20221027 Date Completed: 20221028 Latest Revision: 20221030
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9604470
DOI: 10.3390/ijms232012453
PMID: 36293308
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms232012453